This pilot interventional study enrolled women with obesity and metabolic dysfunction‑associated steatotic liver disease (MASLD) who did not have diabetes. Participants followed a very low‑calorie diet (VLCD) for eight weeks. The trial is registered as NCT04861571 and received ethical approval from the Institutional Review Board at the University of Iowa. The authors report the intervention was well tolerated and that informed consent and institutional oversight procedures were followed.
The VLCD produced clinically meaningful weight loss of approximately 11% from baseline, with adherence reported at roughly 80%. Body composition and cardiometabolic variables improved significantly: reductions in fat mass and waist circumference were observed alongside decreases in blood pressure. Markers of insulin resistance and glycemia improved, including lower insulinemia, improved HOMA‑IR, and reduced HbA1c. Serum triglycerides also declined. The investigators note that standard liver enzyme measures remained unchanged over the 8‑week intervention.
Hepatic steatosis was assessed by the controlled attenuation parameter (CAP). CAP values decreased markedly following the VLCD, indicating a reduction in liver fat. By contrast, measures of liver stiffness did not change over the study period. These imaging findings support substantial short‑term improvement in hepatic steatosis with rapid dietary weight loss, while fibrosis‑related stiffness was not affected within eight weeks.
Untargeted plasma metabolomic profiling identified a metabolic signature characteristic of a catabolic, fat‑oxidative state. Key findings included elevated ketone bodies and broad reductions in circulating amino acid levels. The pattern is consistent with enhanced fatty acid oxidation and shifts in substrate utilization during calorie restriction. Changes in tricarboxylic acid (TCA) cycle intermediates were also reported in the metabolomic dataset.
Correlation analyses linked metabolite shifts to liver fat changes. Specifically, reductions in CAP were positively associated with decreases in multiple amino acids and inversely associated with increases in ketone bodies and TCA cycle intermediates. These relationships indicate distinct metabolite signatures that correspond with improvement in hepatic steatosis during rapid weight loss.
Circulating microRNAs (miRs) did not undergo global, uniform change; rather, a selective subset showed pronounced remodeling and strong associations with clinical measures. The VLCD altered levels of specific circulating miRs, notably miR‑148a‑3p, miR‑140‑3p, miR‑10b‑5p, and miR‑345‑5p. Several of these miRs demonstrated statistically strong associations with CAP and HOMA‑IR, suggesting links between miR changes and both hepatic steatosis and insulin resistance.
The investigators performed integrated correlation and hierarchical clustering analyses to combine the metabolomic and circulating miR datasets. This multi‑omics approach uncovered coordinated metabolite–miRNA modules that grouped biologically related pathways. Identified modules implicated: glucose metabolism, branched‑chain amino acid (BCAA) catabolism, mitochondrial metabolism, purine metabolism, microbial‑derived metabolites, and cellular redox pathways. The authors present these modules as candidate molecular signatures capturing coordinated metabolic adaptation during VLCD‑induced weight loss.
The VLCD intervention was described as well tolerated across the study population, with adherence near 80%. Liver enzyme concentrations were unchanged, and no competing interests were reported by the authors. The study was registered (NCT04861571) and approved by the University of Iowa IRB. The manuscript notes that all relevant ethical guidelines were followed and participant consents were obtained.
As a pilot study, the sample size and study population (women with obesity and MASLD without diabetes) limit generalizability. The report does not provide full participant counts or detailed adverse event tables in the abstract; those details would need to be obtained from the full preprint. The authors state that all data produced in the study are available from them upon reasonable request.
In this pilot cohort, an 8‑week VLCD produced substantial weight loss and marked reductions in hepatic steatosis while inducing coordinated changes in circulating metabolites and a selective set of microRNAs. Metabolomic changes reflected enhanced fatty acid oxidation and a catabolic state, and integrated multi‑omics analyses identified metabolite–miRNA modules linked to glucose and amino acid metabolism, mitochondrial function, purine metabolism, microbial metabolites, and redox biology. The authors propose that circulating metabolite–miRNA modules may serve as candidate biomarkers of therapeutic response in MASLD. Further studies with larger and more diverse cohorts and longer follow‑up would be required to validate these molecular signatures and to assess durability and clinical outcomes.
(Preprint posted September 04, 2026; medRxiv doi provided in source.)